ASTRAZENECA PERU S.A. - Søgeresultater

Den Europæiske Union - engelsk - myHealthbox

xigduo 5 mg/850 mg film-coated tablets

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/850 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

Den Europæiske Union - engelsk - myHealthbox

xigduo 5 mg/1,000 mg film-coated tablets

astrazeneca ab - metformin hydrochloride, dapagliflozin propanediol monohydrate - film-coated tablet (tablet) - 5 mg/1,000 mg - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose-lowering drugs - indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products - in patients already being treated with the combination of dapagliflozin and metformin as separate tablets

USA - engelsk - NLM (National Library of Medicine)

lynparza- olaparib capsule

astrazeneca pharmaceuticals lp - olaparib (unii: woh1jd9ar8) (olaparib - unii:woh1jd9ar8) - olaparib 50 mg - lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline brca -mutated (gbrcam ) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. none. risk summary based on findings in animals and its mechanism of action [see clinical pharmacology (12.1)] , lynparza can cause fetal harm when administered to a pregnant woman. there are no available data on lynparza use in pregnant women to inform the drug associated risk. in an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily [see data] . apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. the estimated background risk of major birth d

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca suxamethonium chloride 100mg/2ml injection bp ampoule

juno pharmaceuticals pty ltd - suxamethonium chloride -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pancuronium bromide 4mg/2ml injection bp ampoule

juno pharmaceuticals pty ltd - pancuronium bromide, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium acetate; sodium chloride; acetic acid; sodium hydroxide - indiactions as at 1 january 1991: 1. as an adjunct to surgical anaesthesia to induce skeletal muscle relaxation to facilitate operative manipulations. the necessary conditions for intubation can be achieved with pancuronium bromide alone or following suxamethonium. 2. pancuronium bromide is also indicated to promote mechanical ventilation by reducing or eliminating spontaneous breathing effort in intensive care patients.